Long Covid Is New Name For Old Syndrome

blog

Long Covid goes by many names. Today, it is no longer a new public health enigma, but the outlook for sufferers is no better than when the condition was first recognized in early 2020. Although its prevalence has recently decreased to 6% of the U.S. adult population, there has been no significant progress in understanding its causes, prevention, or treatment. Long Covid still looms as the national health disaster many predicted. Everyone — patients, support groups, clinicians, researchers, and health care systems — is frustrated by lack of meaningful progress in research and patient care.

On the research side, the U.S. government rapidly anticipated and tried to blunt the force of this national calamity by investing in basic and clinical research. Hopes were raised in December 2020 when Congress provided $1.15 billion over four years to the NIH to launch its long Covid research initiative called RECOVER. The Centers for Disease Control and Prevention additionally initiated its Innovative Support for Patients with Covid-19 Infections Registry (INSPIRE). Veterans Affairs also deployed the nation’s largest health care system in support of LC research.

Now, more than two years down this ambitious path, and with published results emerging, outraged experts and patient advocates say that there is “little to show for it.” The critique is that mostly observational studies have characterized risk factors, demographics, and attributes of the clinical syndrome, but little has emerged that directly contributes to prevention or patient care.

The view from the patient care side is no more optimistic. People with long Covid are subject to stigmatization and feel disempowered as they navigate a fragmented health care system not organized to deliver patient-centric care.

Related: ‘Underwhelming’: NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion

While long Covid’s causes and treatments remain elusive, its health, social, and economic toll is enormous and indisputable. A 2022 paper projected the total U.S. economic impact in quality of life, lost earnings, and medical care spending at $3.7 trillion. That’s $11,000 per capita or 17% of the 2019 gross domestic product. As the country has largely moved on from the acute phase of the pandemic, long Covid has left a trail of frustration, suffering, functional impairment, and disability.

The current grim reality is underscored by the unsatisfying National Institutes of Health guidance that “the best way to prevent long COVID is to avoid getting COVID-19.” Although true, this advice offers scant comfort to the large majority of Americans who have been infected by Covid-19 and to most who are still at risk for new or re-infections — especially now, when there are few societal efforts to prevent transmission.

The solution for this seemingly unsolvable puzzle is hiding in plain sight. Long Covid is a new term coined for an old syndrome that has long bedeviled the ecosystem of clinicians, researchers, patients, support groups, and health care systems. It’s a unifying hypothesis that explains most observed facts around the striking lack of inroads against long Covid.

Long Covid is really not new. It is virtually indistinguishable from the condition long known in the medical lexicon as post-infectious syndrome or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Although some have recognized and studied their similarities, it seems no one has made the simplifying observation that they are essentially the same condition.

In the ME/CFS paradigm, long Covid is not a new condition. Logic and reason dictate that acute SARS-CoV-2 infection causes long Covid.

“Triggers” means a temporal association, but not “cause” in a mechanistic sense — at least not identifiable with currently available scientific tools. This hypothesis has major policy, research, and patient-care best practice implications. It’s our most direct path forward to reset society’s goals, strategies, and expectations for true progress against this public health catastrophe.

Related: Study mapping how SARS-CoV-2 disrupts mitochondria suggests a cause for long Covid

Although much about ME/CFS is still not well-understood, decades of experience and research into this condition could be productively and rapidly applied to long Covid. That approach could help avoid missteps, focus investment priorities, ground societal expectations regarding what is achievable, and improve patient welfare dramatically.

For example, basic research has focused on identifying long Covid laboratory markers and the pathogenesis (mechanism) linking the virus with the symptoms. Researchers are exploring biologically plausible hypotheses including viral persistence, microvascular clots, gut microbiome disruption, and immune system derangements as the mechanism behind long Covid symptoms.

But if long Covid is really a form of ME/CFS, this approach will likely be unrewarding. Decades of ME/CFS research exploring etiology and pathogenesis have been unproductive. The current research directed at finding mechanistic clues to long Covid is a resource-intensive and lengthy uncharted process. It is likely to produce further leads for more research, but with a low ultimate probability of success in helping patients.

There is an already extensive body of patient-care experience, guidance, and resources for best practice to build on in the clinical management of post-infection syndromes. This should be aggressively applied to the benefit of long Covid patients. This approach includes “coordinating clinical care and rehabilitation, reducing health care disparities, and addressing ongoing and complex medical and psychosocial needs.” Patient education and health care workforce training are an essential component in the dissemination of best practices and in setting realistic expectations for prognosis and treatment outcomes. The wheel does not need to be reinvented, only improved. A current consensus long Covid definition is that it is a disorder following acute Covid-19 infection “with symptoms not attributable to any other condition.” It can present with a myriad of more than 200 symptoms referable to any organ system. This is virtually identical to the Institute of Medicine’s 2015 case definition of ME/CFS.

For the sake of definitional clarity, there are a few well-documented consequences of acute Covid-19 that are caused by the SARS-CoV-2 virus. These are MIS-C, myocarditis, and blood clots. Where there are clear objective signs of disease that are diagnosable outside the patient, the illness is excluded from the ME/CFS paradigm. Another exclusion is the post-intensive care syndrome (PICS). According to the CDC, “people experiencing any severe illness, hospitalization, or treatment may develop problems such as PICS. For people who experience PICS following a COVID-19 diagnosis, it is difficult to determine whether these health problems are caused by a severe illness, the virus itself, or a combination of both.”


--Statnews


Author

Steven Phillips  Michelle/ A. Williams
How did you feel after reading this news?

More from Author

PM Prachanda visits Potala Palace, Jokhang Temple

China visit very successful: PM Prachanda

Public holiday in Madhes tomorrow

Pushpa and Anjali relocated to Koshi Tappu